Evidence map›Paper›PMID 33854694›Full record

ArticleOxidative medicine and cellular longevity2021

Xinmailong Attenuates Doxorubicin-Induced Lysosomal Dysfunction and Oxidative Stress in H9c2 Cells via HO-1.

Yu Jiang, Yanjuan Liu, Wen Xiao, Dandan Zhang, Xiehong Liu, Huiqiong Xiao, Sanli You, Lili Yuan

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Emerging Research and Future Directions on Doxorubicin: A Snapshot.Asian Pacific journal of cancer prevention : APJCP · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Pharmaceutical biology · 2022
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yu JiangHunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.ORCID https://orcid.org/0000-0002-2645-3804
Yanjuan LiuHunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.ORCID https://orcid.org/0000-0002-6974-1419
Wen XiaoHunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.ORCID https://orcid.org/0000-0003-0384-1115
Dandan ZhangHunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.ORCID https://orcid.org/0000-0002-5672-1777
Xiehong LiuHunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.ORCID https://orcid.org/0000-0002-1059-790X
Huiqiong XiaoDepartment of Cardiology, Brain Hospital of Hunan Province, Changsha, Hunan, China.ORCID https://orcid.org/0000-0001-8939-8614
Sanli YouDepartment of Cardiology, Brain Hospital of Hunan Province, Changsha, Hunan, China.ORCID https://orcid.org/0000-0002-1458-6861
Lili YuanDepartment of Cardiology, Brain Hospital of Hunan Province, Changsha, Hunan, China.ORCID https://orcid.org/0000-0003-1679-5234
Hunan Normal University · CNHunan Institute of Mental Health · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical use of doxorubicin (DOX) is limited by its cardiotoxicity, which is closely associated with oxidative stress. Xinmailong (XML) is a bioactive peptide extracted from American cockroaches, which has been mainly applied to treat chronic heart failure in China. Our previous study showed that XML attenuates DOX-induced oxidative stress. However, the mechanism of XML in DOX-induced cardiotoxicity remains unclear. Heme oxygenase-1 (HO-1), an enzyme that is ubiquitously expressed in all cell types, has been found to take antioxidant effects in many cardiovascular diseases, and its expression is protectively upregulated under DOX treatment. Lysosome and autophagy are closely involved in oxidative stress as well. It is still unknown whether XML could attenuate doxorubicin-induced lysosomal dysfunction and oxidative stress in H9c2 cells via HO-1. Thus, this study was aimed at investigating the involvement of HO-1-mediated lysosomal function and autophagy flux in DOX-induced oxidative stress and cardiotoxicity in H9c2 cells. Our results showed that XML treatment markedly increased cell proliferation and SOD activity, improved lysosomal function, and ameliorated autophagy flux block in DOX-treated H9c2 cells. Furthermore, XML significantly increased HO-1 expression following DOX treatment. Importantly, HO-1-specific inhibitor (Znpp) or HO-1 siRNA could significantly attenuate the protective effects of XML against DOX-induced cell injury, oxidative stress, lysosomal dysfunction, and autophagy flux block. These results suggest that XML protects against DOX-induced cardiotoxicity through HO-1-mediated recovery of lysosomal function and autophagy flux and decreases oxidative stress, providing a novel mechanism responsible for the protection of XML against DOX-induced cardiomyopathy.

Indexed as

AnimalsAntibiotics, AntineoplasticCell LineDoxorubicinDrug InteractionsDrugs, Chinese HerbalHeme Oxygenase (Decyclizing)LysosomesMyocytes, CardiacOxidative StressRatsAntibiotics, AntineoplasticDoxorubicinDrugs, Chinese HerbalHeme Oxygenase (Decyclizing)Hmox1 protein, ratxinmailong

Identifiers

PMID33854694
PMCPMC8019640
OpenAlexW3147466758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.